Original paper
Pd-L1 Testing Based on The SP142 Antibody in Metastatic Triple-Negative Breast Cancer: Summary of an Expert Round-Table Discussion
Abstract
Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays...
Paper Details
Title
Pd-L1 Testing Based on The SP142 Antibody in Metastatic Triple-Negative Breast Cancer: Summary of an Expert Round-Table Discussion
Published Date
Dec 8, 2020
Journal
Volume
17
Issue
10
Pages
1209 - 1218